Picked for heritage and experience

For hormone-responsive breast cancer

  • Approximately 60% of breast cancers amongst pre-menopausal women are oestrogen-receptor-positive12 and a proportion of these patients may benefit from gonadotropin-releasing hormone (GnRH) agonist therapy
  • This approach works by blocking the production of gonadotropins in the pituitary gland which in turn blocks the release of oestrogen (and progesterone) from the ovaries12–14
  • With blocked or reduced oestrogen, the oestrogen-receptor-positive breast cancer is inhibited from growing12–14

 

  • Prostap 3 DCS is the only three-monthly GnRH agonist preparation licensed for pre- and perimenopausal oestrogen-receptor-positive breast cancer patients3
  • In the early breast cancer setting, GnRH agonist therapy is recommended for up to 5 years in combination with either tamoxifen or an aromatase inhibitor, therefore the convenience of three-monthly administration may make a real difference to the lives of patients3

Contact

If you are a healthcare professional and have a query about Prostap DCS, please call Medical Information on:

03333 000 181

If you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below

    Your Name
    Email
    Phone
    Definition of Role
    Practice address
    Postcode
    *Required fields

    Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 020 3116 8000.

    References

    1. Takeda UK Ltd. Data on file, UK/PRS/2002/0004.
    2. Prostap SR DCS. Summary of Product Characteristics. Available at: www.medicines.org.uk
    3. Prostap 3 DCS. Summary of Product Characteristics. Available at: www.medicines.org.uk
    4. Health and Safety Executive. Health and Safety (Sharp Instruments in Healthcare) Regulations 2013. Available via: www.hse.gov.uk/pubns/hsis7.pdf (last accessed June 2021).
    5. European Agency for Safety and Health at Work. Directive 2010/32/EU – prevention from sharp injuries in the hospital and healthcare sector. Available at: www.osha.europa.eu/en/legislation/directives/council-directive-2010-32-eu-prevention-from-sharp-injuries-in-the-hospital-and-healthcare-sector (last accessed June 2021).
    6. Ogawa Y et al. J Pharm 1989;41(7):439-44.
    7. Abouelfadel Z & Crawford D. Therapeut Clin Risk Manag 2008;4(2):513-26.
    8. The Leuprolide Study Group. N Eng J Med 1984;311:1281-6.
    9. Friedman AJ et al. Fertil Steril 1987;48(4):560-4.
    10. PharmaTimes online. Takeda launces new presentation of Prostap, 2011. Available at: http://www.pharmatimes.com/news/takeda_launches_new_presentation_of_prostap_980760 (last accessed June 2021).
    11. National Institute for Health and Care Excellence (2014) Prostate cancer: diagnosis and management. NICE guideline (CG175).
    12. Goel S et al. Cochrane Database Syst Rev 2009;7(4):CD004562.
    13. Cancer Research UK. Hormone therapy for cancer, Jan 2021. Available at: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/hormone-therapy/for-cancer (last accessed June 2021).
    14. NHS UK. Breast cancer in women – Treatment, September 2016. Available at: https://www.nhs.uk/conditions/breast-cancer/treatment/ (last accessed June 2021).
    15. Zoladex 3.6 mg. AstraZeneca UK. Summary of Product Characteristics. Available at: www.medicines.org.uk (last accessed June 2021).
    16. Decapeptyl SR 3 mg. Ipsen Ltd. Summary of Product Characteristics. Available at: www.medicines.org.uk (last accessed June 2021).

    You are now leaving prostapdcs.co.uk. Takeda are the owners of the following website and control the overall running of the website and Takeda-related content.

    Please confirm if you wish to follow this link.

    Continue

    You are now leaving Prostapdcs.co.uk. Takeda reviews the accuracy and content of its products that are available via the link you have selected. However, Takeda are not the owners of the website and as such do not control the overall running of the website or any non-Takeda-related content.

    Please confirm if you wish to follow this link.

    Continue

    The link you have selected is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.

    Please confirm if you wish to follow this link.

    Continue

    About these calculations

    The table provides a worked example of the PA allowance calculation for a GP in a non-dispensing practice in England.
    The dispensing fees and clawback rates are based on the smallest non-dispensing practice:
    • Clawback rate: 3.17% represents total basic price per month £1-2,000
    • Dispensing Fee: £2.669 represents total prescriptions calculated separately for each individual non-dispensing practitioner up to 449

    Clawback rates and dispensing fees current as of October 2020, please refer to Dispensing Feescales for GMS Contractors in England & Wales (Non Dispensing Practice). Effective 1st October 2020.

    This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Practice Managers. If you are not a Practice Manager, please select the appropriate area of this website from the welcome page.

    No

    I am not a Practice Manager

     Yes

    I am a Practice Manager

    This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Healthcare Professionals. If you are not a Healthcare Professional, please select NO to go back and select the appropriate section of this website for you.

    No

    I am not a Healthcare Professional

     Yes

    I am a Healthcare Professional interested in prostate cancer

     Yes

    I am a Healthcare Professional interested in endometriosis

     Yes

    I am a Healthcare Professional interested in breast cancer

    This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for patients who have been prescribed Prostap DCS.

    If you are not a patient who has been prescribed Prostap DCS, please select the appropriate area of this website from the welcome page.

    No

    I am not a Prostap DCS prescribed patient.

     Yes

    I am a Prostap DCS prescribed patient.
    This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more.